Nhuộm miễn dịch p53 phân biệt giữa bệnh bạch cầu hồng cầu nguyên chất và tăng sinh hồng cầu phản ứng
Tóm tắt
Bệnh bạch cầu hồng cầu nguyên chất (PEL) là một loại bệnh bạch cầu cấp dòng tủy hiếm gặp và hung hãn với tiên lượng kém. Việc chẩn đoán PEL thường là tình huống y tế khẩn cấp, khá thách thức và thường cần chẩn đoán dựa trên loại trừ, đòi hỏi sự phân biệt tỉ mỉ với các sự phát triển hồng cầu không phải u, đặc biệt là tăng sinh/điều hòa hồng cầu rõ rệt. Xét thấy tần suất của các đột biến
Từ khóa
Tài liệu tham khảo
Arber DA, Brunning RD, Orazi A (2017) Pure erythroid leukemia. In: Swerdlow S, Campo E, Harris N et al (eds) WHO Classification of Tumours of Haematopoeitic and Lymphoid Tissues. IARC, Lyon, pp 161–162
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544
Wang SA, Hasserjian RP (2015) Acute erythroleukemias, acute megakaryoblastic leukemias, and reactive mimics. Am J Clin Pathol 144(1):44–60. https://doi.org/10.1309/ajcprkyat6ezqhc7
Raess PW, Paessler ME, Bagg A, Weiss MJ, Choi JK (2012) α-Hemoglobin-stabilizing protein is a sensitive and specific marker of erythroid precursors. Am J Surg Pathol 36(10):1538–1547. https://doi.org/10.1097/PAS.0b013e31825fa501
Yu H, Pinkus JL, Pinkus GS (2016) α-Hemoglobin-stabilizing protein: an effective marker for erythroid precursors in bone marrow biopsy specimens. Appl Immunohistochem Mol Morphol 24(1):51–56. https://doi.org/10.1097/pai.0000000000000139
Lee WY, Weinberg OK, Pinkus GS (2017) GATA1 is a sensitive and specific nuclear marker for erythroid and megakaryocytic lineages. Am J Clin Pathol 147(4):420–426. https://doi.org/10.1093/ajcp/aqx018
Wolgast LR, Cannizzarro LA, Ramesh KH, Xue X, Wang D, Bhattacharyya PK, Gong JZ, McMahon C, Albanese JM, Sunkara JL, Ratech H (2011) Spectrin isoforms: differential expression in normal hematopoiesis and alterations in neoplastic bone marrow disorders. Am J Clin Pathol 136(2):300–308. https://doi.org/10.1309/ajcpsa5rnm9igfjf
Reinig EF, Greipp PT, Chiu A, Howard MT, Reichard KK (2018) De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity. Mod Pathol 31(5):705–717. https://doi.org/10.1038/modpathol.2017.175
Dong HY, Wilkes S, Yang H (2011) CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages. Am J Surg Pathol 35(5):723–732. https://doi.org/10.1097/pas.0b013e31821247a8
Wang W, Wang SA, Medeiros J, Khoury JD (2017) Pure erythroid leukemia. Am J Hematol 92:292–296. https://doi.org/10.1002/ajh.24626
Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, Antipin J, Reva B, Koff A, Nimer SD (2009) p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4(1):37–48. https://doi.org/10.1016/j.stem.2008.11.006
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M (2017) More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(18):2584–2587
International Standing Committee on Human Cytogenetic Nomenclature (2020) An International System for Human Cytogenetic Nomenclature. In: McGowan-Jordan J, Hastings RJ, Moore S (eds) Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Karger, Basel, Switzerland
Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, Philip JKSS, Kurzer JH, Rogers HJ, Nardi V, Stone RM, Garcia JS, Hsi ED, Bagg A, Wang SA, Orazi A, Arber DA (2019) Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol 32(9):1373–1385. https://doi.org/10.1038/s41379-019-0263-3
Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT, George TI, Czuchlewski DR, Foucar K, Rogers HJ, Hsi ED, Bryan Rea B, Bagg A, Dal Cin P, Zhao C, Kelley TW, Verstovsek S, Bueso-Ramos C, Orazi A (2016) Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol 29(8):854–864. https://doi.org/10.1038/modpathol.2016.75
Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Göhring G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backstrom J, Fenaux P, MacBeth KJ, Hellström-Lindberg E (2014) p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica 99(6):1041–1049. https://doi.org/10.3324/haematol.2013.098103
Bártek J, Bártková J, Vojtĕsek B, Stasková Z, Lukás J, Rejthar A, Kovarík J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6(9):1699–1703
Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9(10):701–713. https://doi.org/10.1038/nrc2693